Miki Sogi, an analyst from Bernstein, maintained the Hold rating on Takeda Pharmaceutical Co (TKPHF – Research Report). The associated price ...

TOKYO (Reuters) - Japan's biggest drugmaker Takeda Pharmaceutical posted third-quarter profits on Thursday that trailed analyst estimates, as the company continues a restructuring push.

Let me start, I’d like to remind everyone that we’ll be discussing forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may ...

“The announcement of our new share buyback program, approved by Takeda’s Board of Directors, demonstrates our commitment to shareholder returns.” FINANCIAL HIGHLIGHTS for FY2024 Q3 YTD Ended ...

TOKYO, Jan 30 (Reuters) - Takeda Pharmaceutical (4502.T), opens new tab said on Thursday its CEO Christophe Weber will retire after more than a decade at the helm of Japan's biggest drugmaker as ...

Takeda (NYSE:TAK) ADRs traded higher in the premarket on Thursday after the Japanese drugmaker raised its full-year outlook with its Q3 FY24 results and named Julie Kim, head of its U.S. business ...

Takeda has returned to BridGene Biosciences for another small-molecule collaboration—this time focused on immunology as well as neurology. BridGene’s pursuit of undruggable targets is enabled ...

Takeda continues to advance multiple late-stage programs and is on track for three Phase 3 data readouts within the calendar year 2025. The company expects three regulatory filings in FY2025 ...

Additional Information About Takeda’s FY2024 Q3 YTD Results For more details about Takeda’s FY2024 Q3 YTD results, commercial progress, pipeline updates and other financial information ...